Circulation, Vol 83, 1333-1342, Copyright © 1991 by American Heart Association
Y Christen, B Waeber, J Nussberger, M Porchet, RM Borland, RJ Lee, K Maggon, L Shum, PB Timmermans and HR Brunner
BACKGROUND. The purpose of the present study was to assess the inhibitory
effect of DuP 753, an orally active angiotensin II receptor antagonist, on
the pressor action of exogenous angiotensin I and II in healthy male
volunteers. METHODS AND RESULTS. In the first study (single-dose study),
eight volunteers were included in a 2-day protocol repeated four times at
1-week intervals. In each phase, a different dose of drug (2.5, 5, 10, 20,
or 40 mg) or placebo was given. The peak systolic blood pressure response
to a test-dose of angiotensin I was determined serially before and after
oral administration of DuP 753 by continuously monitoring finger blood
pressure using a photoplethysmographic method. DuP 753 reduced the systolic
blood pressure response to angiotensin I in a dose-dependent fashion.
Three, 6, and 13 hours after the 40-mg dose, blood pressure response
decreased to 31 +/- 5%, 37 +/- 6%, and 45 +/- 3% of the control values
(mean +/- SEM, n = 7), respectively. In the second study, 29 volunteers
were treated for 8 days with either a placebo or DuP 753 (5, 10, 20, or 40
mg p.o. q.d.) and challenged on the first, fourth, and eighth days with
bolus injections of angiotensin II. Again, the inhibitory effect on the
systolic blood pressure response to angiotensin II was clearly dose
dependent. Six hours after 40 mg DuP 753, the systolic blood pressure
response to the test-dose of angiotensin II was reduced to 37 +/- 7%, 40
+/- 4%, and 38 +/- 6% of baseline values (mean +/- SEM, n = 6) on days 1,
4, and 8, respectively. With this latter dose, there was still a blocking
effect detectable 24 hours after the drug. Similar to angiotensin
converting enzyme and renin inhibitors, DuP 753 induced a dose-dependent
increase in plasma renin that was more pronounced on the eighth than on the
first day of drug administration. In these normal volunteers, no consistent
clinically significant side effects were observed. There was no evidence
for an agonist effect. CONCLUSIONS. DuP 753 appears to be a well-tolerated,
orally active, potent, and long- lasting antagonist of angiotensin II in
men.
ARTICLES
Oral administration of DuP 753, a specific angiotensin II receptor antagonist, to normal male volunteers. Inhibition of pressor response to exogenous angiotensin I and II
Hypertension Division, University Hospital, Lausanne, Switzerland.
This article has been cited by other articles:
 |
|
 |
|
  D. J. Campbell, J. Nussberger, M. Stowasser, A.H. J. Danser, A. Morganti, E. Frandsen, and J. Menard Activity Assays and Immunoassays for Plasma Renin and Prorenin: Information Provided and Precautions Necessary for Accurate Measurement Clin. Chem., May 1, 2009; 55(5): 867 - 877. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Fournier, G. Choukroun, S. S. Modeliar, O. Godefroy, J.-M. Achard, J. Wang, and F. Messerli Does the MOSES Trial Establish Superiority of AT1-Receptor Blockers Over Dihydropyridine/Calcium Antagonists in Secondary Stroke Prevention? Stroke, February 1, 2006; 37(2): 336 - 337. [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Oishi, R. Ozono, Y. Yano, Y. Teranishi, M. Akishita, M. Horiuchi, T. Oshima, and M. Kambe Cardioprotective Role of AT2 Receptor in Postinfarction Left Ventricular Remodeling Hypertension, March 1, 2003; 41(3): 814 - 818. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Forclaz, M. Maillard, J. Nussberger, H. R. Brunner, and M. Burnier Angiotensin II Receptor Blockade: Is There Truly a Benefit of Adding an ACE Inhibitor? Hypertension, January 1, 2003; 41(1): 31 - 36. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Kurisu, R. Ozono, T. Oshima, M. Kambe, T. Ishida, H. Sugino, H. Matsuura, K. Chayama, Y. Teranishi, O. Iba, et al. Cardiac Angiotensin II Type 2 Receptor Activates the Kinin/NO System and Inhibits Fibrosis Hypertension, January 1, 2003; 41(1): 99 - 107. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. M. Carey, N. L. Howell, X.-H. Jin, and H. M. Siragy Angiotensin Type 2 Receptor-Mediated Hypotension in Angiotensin Type-1 Receptor-Blocked Rats Hypertension, December 1, 2001; 38(6): 1272 - 1277. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Burnier Angiotensin II Type 1 Receptor Blockers Circulation, February 13, 2001; 103(6): 904 - 912. [Full Text] [PDF]
|
|
|
|
|
|
S. G. Myerson, H. E. Montgomery, M. Whittingham, M. Jubb, M. J. World, S. E. Humphries, and D. J. Pennell Left Ventricular Hypertrophy With Exercise and ACE Gene Insertion/Deletion Polymorphism : A Randomized Controlled Trial With Losartan Circulation, January 16, 2001; 103(2): 226 - 230. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M.-H. Liu, H. S. Floten, A. P. Furnary, A. P.C. Yim, and G.-W. He Inhibition of vasoconstriction by angiotensin receptor antagonist GR117289C in arterial grafts Ann. Thorac. Surg., December 1, 2000; 70(6): 2064 - 2069. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. P. Maillard, J. Rossat, H.-R. Brunner, and M. Burnier Tasosartan, Enoltasosartan, and Angiotensin II Receptor Blockade: The Confounding Role of Protein Binding J. Pharmacol. Exp. Ther., November 1, 2000; 295(2): 649 - 654. [Abstract] [Full Text]
|
|
|
|
|
|
Y. Xu, A. S. Clanachan, and B. I. Jugdutt Enhanced Expression of Angiotensin II Type 2 Receptor, Inositol 1,4,5-Trisphosphate Receptor, and Protein Kinase C{epsilon} During Cardioprotection Induced by Angiotensin II Type 2 Receptor Blockade Hypertension, October 1, 2000; 36(4): 506 - 510. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Hanon, P. Vijayaraman, E. H Sonnenblick, and T. H Le Jemtel Persistent formation of angiotensin II despite treatment with maximally recommended doses of angiotensin converting enzyme inhibitors in patients with chronic heart failure Journal of Renin-Angiotensin-Aldosterone System, June 1, 2000; 1(2): 147 - 150. [PDF]
|
|
|
|
|
|
Yi Xu, V. Menon, and B. I Jugdutt Cardioprotection after angiotensin II type 1 blockade involves angiotensin II type 2 receptor expression and activation of protein kinase C-{varepsilon} in acutely reperfused myocardial infarction in the dog: Effect of UP269-6 and losartan on AT1- and AT2-receptor expression and IP3 receptor and PKC{varepsilon} proteins Journal of Renin-Angiotensin-Aldosterone System, June 1, 2000; 1(2): 184 - 195. [Abstract] [PDF]
|
|
|
|
 |
|
 S. Arima and S. Ito Angiotensin II type 2 receptors in the kidney: evidence for endothelial-cell-mediated renal vasodilatation Nephrol. Dial. Transplant., April 1, 2000; 15(4): 448 - 451. [Full Text] [PDF]
|
|
|
|
 |
|
 T. Matsumoto, R. Ozono, T. Oshima, H. Matsuura, T. Sueda, G. Kajiyama, and M. Kambe Type 2 angiotensin II receptor is downregulated in cardiomyocytes of patients with heart failure Cardiovasc Res, April 1, 2000; 46(1): 73 - 81. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. P. Jorde, P. V. Ennezat, J. Lisker, V. Suryadevara, J. Infeld, S. Cukon, A. Hammer, E. H. Sonnenblick, and T. H. Le Jemtel Maximally Recommended Doses of Angiotensin-Converting Enzyme (ACE) Inhibitors Do Not Completely Prevent ACE-Mediated Formation of Angiotensin II in Chronic Heart Failure Circulation, February 29, 2000; 101(8): 844 - 846. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. W. O'Brien, Y. Xu, V. Menon, and B. I. Jugdutt Efficacy of Pretreatment With the Angiotensin II Type 1 Receptor Blocker UP269-6 and Losartan in the Dog: Effect on Hemodynamics and Ischemia-Reperfusion Journal of Cardiovascular Pharmacology and Therapeutics, January 1, 2000; 5(2): 129 - 137. [Abstract] [PDF]
|
|
|
|
|
|
B. I. Jugdutt, Yi Xu, M. Balghith, R. Moudgil, and V. Menon Cardioprotection Induced by AT1R Blockade After Reperfused Myocardial Infarction: Association With Regional Increase in AT2R, IP3R and PKC{varepsilon} Proteins and cGMP Journal of Cardiovascular Pharmacology and Therapeutics, January 1, 2000; 5(4): 301 - 311. [Abstract] [PDF]
|
|
|
|
 |
|
 N Girgrah, P Liu, J Collier, L Blendis, and F Wong Haemodynamic, renal sodium handling, and neurohormonal effects of acute administration of low dose losartan, an angiotensin II receptor antagonist, in preascitic cirrhosis Gut, January 1, 2000; 46(1): 114 - 120. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Gunasegaram, R. S. Haworth, D. J. Hearse, and M. Avkiran Regulation of Sarcolemmal Na+/H+ Exchanger Activity by Angiotensin II in Adult Rat Ventricular Myocytes : Opposing Actions via AT1 Versus AT2 Receptors Circ. Res., November 12, 1999; 85(10): 919 - 930. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Mazzolai, M. Maillard, J. Rossat, J. Nussberger, H. R. Brunner, and M. Burnier Angiotensin II Receptor Blockade in Normotensive Subjects : A Direct Comparison of Three AT1 Receptor Antagonists Hypertension, March 1, 1999; 33(3): 850 - 855. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. R. Marino, K. M. Langenbacher, N. F. Ford, R. H. Raymond, J. Manning, O. Vesterqvist, E. Cooper Shamblen, and K. C. Lasseter Pharmacodynamics and Pharmacokinetics of Irbesartan in Patients With Mild to Moderate Hypertension Journal of Cardiovascular Pharmacology and Therapeutics, January 1, 1999; 4(2): 67 - 75. [Abstract] [PDF]
|
|
|
|
|
|
H. Matsubara Pathophysiological Role of Angiotensin II Type 2 Receptor in Cardiovascular and Renal Diseases Circ. Res., December 14, 1998; 83(12): 1182 - 1191. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Tsutsumi, H. Matsubara, N. Ohkubo, Y. Mori, Y. Nozawa, S. Murasawa, K. Kijima, K. Maruyama, H. Masaki, Y. Moriguchi, et al. Angiotensin II Type 2 Receptor Is Upregulated in Human Heart With Interstitial Fibrosis, and Cardiac Fibroblasts Are the Major Cell Type for Its Expression Circ. Res., November 16, 1998; 83(10): 1035 - 1046. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. P. R. M. Osterop, M. J. M. Kofflard, L. A. Sandkuijl, F. J. t. Cate, R. Krams, M. A. D. H. Schalekamp, and A. H. J. Danser AT1 Receptor A/C1166 Polymorphism Contributes to Cardiac Hypertrophy in Subjects With Hypertrophic Cardiomyopathy Hypertension, November 1, 1998; 32(5): 825 - 830. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Richer, P. Bruneval, J. Menard, and J.-F. Giudicelli Additive Effects of Enalapril and Losartan in (mREN-2)27 Transgenic Rats Hypertension, February 1, 1998; 31(2): 692 - 698. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Ohkubo, H. Matsubara, Y. Nozawa, Y. Mori, S. Murasawa, K. Kijima, K. Maruyama, H. Masaki, Y. Tsutumi, Y. Shibazaki, et al. Angiotensin Type 2 Receptors Are Reexpressed by Cardiac Fibroblasts From Failing Myopathic Hamster Hearts and Inhibit Cell Growth and Fibrillar Collagen Metabolism Circulation, December 2, 1997; 96(11): 3954 - 3962. [Abstract] [Full Text]
|
|
|
|
|
|
T. Rosenthal, Y. Erlich, E. Rosenmann, and A. Cohen Effects of Enalapril, Losartan, and Verapamil on Blood Pressure and Glucose Metabolism in the Cohen-Rosenthal Diabetic Hypertensive Rat Hypertension, June 1, 1997; 29(6): 1260 - 1264. [Abstract] [Full Text]
|
|
|
|
|
|
D. G Kiely, R. I Cargill, N. M Wheeldon, W. J Coutie, and B. J Lipworth Haemodynamic and endocrine effects of type 1 angiotensin II receptor blockade in patients with hypoxaemic cor pulmonale Cardiovasc Res, January 1, 1997; 33(1): 201 - 208. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. K. Gandhi, D. H. Ryder, and N. J. Brown Losartan Blocks Aldosterone and Renal Vascular Responses to Angiotensin II in Humans Hypertension, December 1, 1996; 28(6): 961 - 966. [Abstract] [Full Text]
|
|
|
|
 |
|
 F. H. Messerli, M. A. Weber, and H. R. Brunner Angiotensin II Receptor Inhibition: A New Therapeutic Principle Arch Intern Med, September 23, 1996; 156(17): 1957 - 1965. [Abstract] [PDF]
|
|
|
|
 |
|
 M. T. Velasquez Angiotensin II Receptor Blockers: A New Class of Antihypertensive Drugs Arch Fam Med, June 1, 1996; 5(6): 351 - 356. [Abstract] [PDF]
|
|
|
|
|
|
J. H. Bauer and G. P. Reams The Angiotensin II Type 1 Receptor Antagonists: A New Class of Antihypertensive Drugs Arch Intern Med, July 10, 1995; 155(13): 1361 - 1368. [Abstract] [PDF]
|
|
|
|
|
|
B. A. Soffer, J. T. Wright Jr, J. H. Pratt, B. Wiens, A. I. Goldberg, and C. S. Sweet Effects of Losartan on a Background of Hydrochlorothiazide in Patients With Hypertension Hypertension, July 1, 1995; 26(1): 112 - 117. [Abstract] [Full Text]
|
|
|
|
|
|
A. H. Gradman, K. E. Arcuri, A. I. Goldberg, L. S. Ikeda, E. B. Nelson, D. B. Snavely, and C. S. Sweet A Randomized, Placebo-Controlled, Double-Blind, Parallel Study of Various Doses of Losartan Potassium Compared With Enalapril Maleate in Patients With Essential Hypertension Hypertension, June 1, 1995; 25(6): 1345 - 1350. [Abstract] [Full Text]
|
|
|
|
|
|
M. Burnier, M. Hagman, J. Nussberger, J. Biollaz, C. Armagnac, R. Brouard, B. Waeber, and H. R. Brunner Short-term and Sustained Renal Effects of Angiotensin II Receptor Blockade in Healthy Subjects Hypertension, April 1, 1995; 25(4): 602 - 609. [Abstract] [Full Text]
|
|
|
|
|
|
I. Crozier, H. Ikram, N. Awan, J. Cleland, N. Stephen, K. Dickstein, M. Frey, J. Young, G. Klinger, L. Makris, et al. Losartan in Heart Failure : Hemodynamic Effects and Tolerability Circulation, February 1, 1995; 91(3): 691 - 697. [Abstract] [Full Text]
|
|
|
|
|
|
E. Delacretaz, J. Nussberger, J. Biollaz, B. Waeber, and H. R. Brunner Characterization of the Angiotensin II Receptor Antagonist TCV-116 in Healthy Volunteers Hypertension, January 1, 1995; 25(1): 14 - 21. [Abstract] [Full Text]
|
|
|
|
|
|
A. H. van den Meiracker, P. J.J. Admiraal, J. A. Janssen, J.-M. Kroodsma, W. A.M. de Ronde, F. Boomsma, J. Sissmann, P.J. Blankestijn, P. G.M. Mulder, A. J. Man in `t Veld, et al. Hemodynamic and Biochemical Effects of the AT1 Receptor Antagonist Irbesartan in Hypertension Hypertension, January 1, 1995; 25(1): 22 - 29. [Abstract] [Full Text]
|
|
|
|
|
|
M. R. Goldberg, T. E. Bradstreet, E. J. McWilliams, W. K. Tanaka, S. Lipert, T. D. Bjornsson, S. A. Waldman, B. Osborne, L. Pivadori, G. Lewis, et al. Biochemical Effects of Losartan, a Nonpeptide Angiotensin II Receptor Antagonist, on the Renin-Angiotensin-Aldosterone System in Hypertensive Patients Hypertension, January 1, 1995; 25(1): 37 - 46. [Abstract] [Full Text]
|
|